Safety, tolerability, pharmacokinetics, and pharmacodynamics of LW402, a preferential Janus kinase 1 inhibitor in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial
Authors:
Open Access
- 29 April 2026
- journal article
- clinical trial-article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1784350
Abstract
Introduction: This clinical trial aimed to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of LW402, a preferential JAK1 inhibitor, in healthy participants, so as to provide support for its further development in treating autoimmune diseases. Methods: The study included two phases: a single ascending dose (10–400 mg) with 54 participants and a multiple ascending dose (50–150 mg, b.i.d for 6 days plus a single dose on day 7) with 36 participants. Safety, PK (from timed blood samples), and PD (JAK1/JAK2 signaling) were evaluated. Results: No serious adverse events were reported; only mild treatment-emergent adverse events (TEAEs), such as sinus bradycardia and gastrointestinal issues, occurred. LW402 was rapidly absorbed (median t max : 0.42–1.0 hours), with slightly super-proportional exposure and minimal accumulation, and preferentially inhibited JAK1-mediated signaling. Discussion: LW402’s favorable safety profile, predictable PK characteristics, and selective JAK1 inhibition collectively support its continued development for the treatment of autoimmune diseases. Clinical Trial Registration: http://www.chinadrugtrials.org.cn , identifier CTR20201897.Keywords
This publication has 24 references indexed in Scilit:
- A Study on the Safety, Pharmacokinetics, and Pharmacodynamics of H018 Tablets, a Selective JAK1 Inhibitor, Upon Single- and Multiple-Dose Administration in Chinese Healthy SubjectsClinical Drug Investigation, 2025
- Population pharmacokinetic/pharmacodynamic modeling of H018, a selective JAK1 inhibitor, in healthy Chinese volunteersEuropean Journal of Pharmaceutical Sciences, 2024
- Randomized, double-blinded, placebo-controlled phase I study of the pharmacokinetics, pharmacodynamics, and safety of KL130008, a novel oral JAK inhibitor, in healthy subjectsEuropean Journal of Pharmaceutical Sciences, 2022
- Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trialJournal of the American Academy of Dermatology, 2022
- Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial ProgramAmerican Journal of Clinical Dermatology, 2021
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failureAmerican Journal of Hematology, 2020
- Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy ParticipantsClinical Pharmacology in Drug Development, 2019
- Diagnosis and Management of Rheumatoid ArthritisJAMA, 2018
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF‐06700841) in Healthy Subjects and Patients With Plaque PsoriasisThe Journal of Clinical Pharmacology, 2017
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteersThe Journal of Clinical Pharmacology, 2014